Literature DB >> 3918106

Interferon-gamma enhances induction of lymphotoxin in recombinant interleukin 2-stimulated peripheral blood mononuclear cells.

L P Svedersky, G E Nedwin, D V Goeddel, M A Palladino.   

Abstract

Human peripheral blood mononuclear cells (PBMC) were induced by recombinant human interleukin 2 (rIL 2) to secrete lymphotoxin (LT) and interferon-gamma (IFN-gamma). Induction of both LT and IFN-gamma by rIL 2 is regulated at the transcriptional level. Treatment of PBMC with rIL 2 in combination with recombinant human IFN-gamma (rIFN-gamma) resulted in an earlier appearance of LT mRNA and an augmented production of LT than did rIL 2 treatment alone. IFN-gamma alone had no effect on production of either LT or its mRNA. PBMC cultured in the presence of rIL 2 plus anti-rIFN-gamma resulted in decreased LT production. Only a 15-min incubation of PBMC with rIL 2 is needed to stimulate LT production, whereas 3 hr is necessary for IFN-gamma production. These results suggest that rIL 2, in addition to being a T cell growth factor, may exhibit other activities through induction of LT and IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918106

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Production of interferon and tumour necrosis factor by cloned human natural cytotoxic lymphocytes and T cells.

Authors:  S E Christmas; A Meager; M Moore
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

2.  Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.

Authors:  A S Chong; A Aleksijevic; P Scuderi; E M Hersh; W J Grimes
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.

Authors:  J W Mier; G Vachino; J W van der Meer; R P Numerof; S Adams; J G Cannon; H A Bernheim; M B Atkins; D R Parkinson; C A Dinarello
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

4.  Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection.

Authors:  D M Williams; L F Bonewald; G D Roodman; G I Byrne; D M Magee; J Schachter
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

5.  Expression of genes for interleukin-1 alpha and tumour necrosis factor-alpha in newborn mice.

Authors:  M Lipoldová; V Holán
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

6.  Gamma interferon-mediated cytotoxicity related to murine Chlamydia trachomatis infection.

Authors:  G I Byrne; B Grubbs; T J Marshall; J Schachter; D M Williams
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

7.  Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level.

Authors:  J Andersson; S Nagy; C G Groth; U Andersson
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

8.  The genes for tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse.

Authors:  S A Nedospasov; B Hirt; A N Shakhov; V N Dobrynin; E Kawashima; R S Accolla; C V Jongeneel
Journal:  Nucleic Acids Res       Date:  1986-10-10       Impact factor: 16.971

9.  Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC).

Authors:  M Ernst; P Kern; H D Flad; A J Ulmer
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

10.  Distribution and kinetics of superantigen-induced cytokine gene expression in mouse spleen.

Authors:  M Bette; M K Schäfer; N van Rooijen; E Weihe; B Fleischer
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.